ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2624 • 2013 ACR/ARHP Annual Meeting

    Evaluation of Asymptomatic Venous Disease By Venous Doppler Ultrasonography in Patients With Behcet’s Disease

    Fatma Alibaz-Oner1, Emrah Karatay2, Ihsan Nuri Akpinar2, Tülin Ergun3 and Haner Direskeneli1, 1Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 2Radiology, Marmara University, School of Medicine, Istanbul, Turkey, 3Dermatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: One of the major causes of mortality and morbidity in Behcet’s disease (BD), especially in young males of Mediterranean origin, is vascular involvement. A…
  • Abstract Number: 2625 • 2013 ACR/ARHP Annual Meeting

    Biologic Therapy In Refractory Uveitis Of Behcet’s Syndrome: Switching and Dose Modification. Multicenter Study Of 124 Patients

    F. Ortiz-Sanjuán1, Vanesa Calvo-Río2, Ricardo Blanco3, Emma Beltrán4, Juan Sánchez-Bursón5, Marina Mesquida6, Alfredo M. Adan6, M Hernandez Grafella7, E Valls Pascual8, L Martínez-Costa9, A Sellas-Fernàndez10, Miguel Cordero-Coma11, Manuel Diaz-llopis12, David Salom12, Jl García Serrano13, Norberto Ortego13, JM Herreras14, Alejandro Fonollosa15, A Aparicio16, O Maíz17, A Blanco18, I Torre19, Cruz Fernández-Espartero20, V Jovani21, D Peitado-Lopez22, Esperanza Pato23, J Cruz24, J. Carlos Fernandez-Cid25, Elena Aurrecoechea26, M García27, M Caracuel28, Carlos Montilla29, A Atanes30, F Francisco31, S Insua32, S González-Suárez33, A Sánchez-Andrade34, F Gamero35, Luis Linares36, F Romero-Bueno37, J García38, AJ García González39, Raquel Almodovar40, E Minguez41, C Carrasco Cubero42, Alejandro Olivé Marqués43, J Vázquez44, O Ruiz Moreno45, F Jimenez-Zorzo45, J Manero45, Javier Loricera2 and Miguel Angel González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Hospital Marques de Valdecilla, Santander, Spain, 4Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 5Hospital de Valme. Sevilla, Sevilla, Spain, 6Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, 8Rheumatology, Hospital Peset Valencia, Valencia, Spain, 9Ophthalmology, Hospital Peset Valencia, Valencia, Spain, 10Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, 11Departament of Ophthalmology, Hospital de León, León, Spain, 12Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, 13Hospital San Cecilio. Granada, Granada, Spain, 14Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, 15Ophtalmology Service, Hospital de Cruces. Bilbao, Baracaldo, Spain, 16Rheumatology., Hospital de Toledo., Toledo, Spain, 17Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, 18Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, 19Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, 20Servicio de Reumatología, Hospital Universitario de Móstoles. Madrid, Madrid, Spain, 21Rheumatology., Hospital General de Alicante., Alicante, Spain, 22Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, 23Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, 24Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, 25Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, 26Rheumatology, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, 27Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, 28Rheumatology., Hospital de Córdoba., Córdoba, Spain, 29Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, 30Rheumatology., HUCA La Coruña., A Coruña, Spain, 31Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, 32Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, 33Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, 34Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, 35Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, 36Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, 37Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, 38Rheumatology, Hospital 12 de Octubre. Madrid, Madrid, Spain, 39Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, 40Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, 41Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, 42Rheumatology., Hospital de Mérida, Mérida, Spain, 43Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, 44Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, 45Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain

    Background/Purpose: Several situations can be observed in patients undergoing biologic therapy in uveitis associated to Behçet´s syndrome (BS): a) Patients are switched to another therapy…
  • Abstract Number: 2626 • 2013 ACR/ARHP Annual Meeting

    Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome

    Vedat Hamuryudan1, Gulen Hatemi2, Yilmaz Ozyazgan2, Didar Ucar2, Sebahattin Yurdakul2, Emire Seyahi2, Koray Tascilar2, Serdal Ugurlu2 and Hasan Yazici3, 1Division of Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2Cerrahpasa Medical Faculty University of Istanbul, Behcet's Syndrome Research Center, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, 3Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

    Background/Purpose: Uncontrolled studies suggest a beneficial effect of infliximab in the treatment of severe uveitis of BS. The majority of these studies had short observation…
  • Abstract Number: 2627 • 2013 ACR/ARHP Annual Meeting

    Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease

    Akihiko Nakabayashi1, Toru Hirano2, Yoshihiro Hishitani2, Keisuke Hagihara3, Kei Nakai4, Kouji Nishida4 and Atsushi Kumanogoh2, 1Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, 2Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, 3Department of Kampo Medicine, Osaka University Graduate School of Medicine, Suita, Japan, 4Department of Ophthalmology, Osaka University Graduate School of Medicine, suita, Japan

    Background/Purpose: Infliximab, a chimeric monoclonal antibody against TNF-a, is expected to improve prognosis of visual function in patients with severe and refractory uveitis of Behçet's…
  • Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis

    Mitsuhiro Takeno1, Kayo Terauchi1, Yohei Kirino1,2, Ryusuke Yoshimi1, Nobuhisa Mizuki2, Etsuko Shibuya3 and Yoshiaki Ishigatsubo2, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
  • Abstract Number: 2629 • 2013 ACR/ARHP Annual Meeting

    Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet’s Disease ?

    Fatma Alibaz-Oner1, Gonca Mumcu2, Zeynep Kubilay3, Gülsen Ozen4, Gülce Celik3, Aslı Karadeniz3, Meryem Can5, Sibel Yılmaz Oner1, Nevsun Inanc6, Pamir Atagunduz7, Tülin Ergun8 and Haner Direskeneli1, 1Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 2Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 3Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, 4Rheumatology, Marmara University School of Medicine., Istanbul, Turkey, 5Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 6Marmara University School of Medicine, Istanbul, Turkey, 7Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 8Dermatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: The clinical course of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing nature is unsufficiently explored. As complete remission should be aimed…
  • Abstract Number: 2630 • 2013 ACR/ARHP Annual Meeting

    Low Medication Adherence Is Observed In Behcet’s Disease

    Gonca Mumcu1, Ali Taze2, Esra Kula2, Semiha Yemez2, Silay Eksi2, Leyla Köksal3, Fatma Alibaz-Oner4, Sibel Yilmaz Oner4, Pamir Atagündüz4, Nevsun Inanc5, Tülin Ergun6 and Haner Direskeneli4, 1Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 2Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 3Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 4Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 5Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 6Dermatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: Symptom-control with reduction of mortality and morbidityare the main treatment goalsin Behcet’s Disease (BD). However, similar to other chronic disorders,  increased unnecessary visits, hospitalisation…
  • Abstract Number: 2631 • 2013 ACR/ARHP Annual Meeting

    Fertility In Behçet’s Syndrome: Structured Interview In A Multidisciplinary Center

    Caner Saygin1, Didem Uzunaslan1, Gulen Hatemi2, Koray Tascilar1 and Hasan Yazici3, 1University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 3Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

    Background/Purpose: Behçet’s Syndrome (BS) follows an active course during the child-bearing years in both men and women. Whether fertility is decreased among the BS patients…
  • Abstract Number: 2632 • 2013 ACR/ARHP Annual Meeting

    Long Term Outcome Of Neuro-Behçet’s Disease

    Nicolas Noel1, Remy Bernard2, Bertrand Wechsler3, Matthieu Resche-Rigon2, Du Boutin4, Jean-Charles Piette5, Aurélie Drier6, Didier Dormont6, Patrice Cacoub4 and David Saadoun7, 1APHP, Hopital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France, 2Biostatistics, Hopital Saint-Louis, Paris, France, 3Internal Medecine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 4Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 5Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 6Neuroradiology, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 7DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France

    Background/Purpose: Neurological involvement occurs in 5.3 to up to 59% of patients with Behçet’s disease (BD). Although the clinical and imaging features of neuro-Behçet’s disease…
  • Abstract Number: 2633 • 2013 ACR/ARHP Annual Meeting

    Clinical Spectrum Of Cutaneous Vasculitis

    Javier Loricera1, Vanesa Calvo-Río1, Francisco Ortiz-Sanjuan2, Héctor Fernández-Llaca3, Marcos A. González-López4, Lino Álvarez5, M. Carmen González-Vela6, Domingo González-Lamuño7, Cristina Mata2, Javier Rueda-Gotor8, Víctor M. Martínez-Taboada9, Miguel Angel González-Gay2 and Ricardo Blanco10, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 3Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 4Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 6Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 7Pediatrics, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, 8Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 9Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, 10Hospital Marques de Valdecilla, Santander, Spain

    Background/Purpose: Cutaneous vasculitis (CV) encompasses a large and heterogeneous set of syndromes characterized by inflammation of the skin vessels. The most common clinical manifestation is…
  • Abstract Number: 2634 • 2013 ACR/ARHP Annual Meeting

    Henoch-Schönlein Purpura: Clinical Spectrum Of The Disease In 417 Patients From A Single Center

    F. Ortiz-Sanjuán1, Vanesa Calvo-Río2, Javier Loricera1, C Mata1, L Martín Penagos3, L Alvarez4, M. Carmen González-Vela5, D González-Lamuño4, Javier Rueda-Gotor6, Héctor Fernández-Llaca7, Marcos A. González-López8, Susana Armesto9, M. Enriqueta Peiró2, M. Arias3, Miguel Angel Gonzalez-Gay1 and Ricardo Blanco10, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Nephrology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 4Pediatrics, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 5Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 6Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 7Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 8Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 9Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 10Hospital Marques de Valdecilla, Santander, Spain

    Background/Purpose: The severity of clinical features and the outcome in the different series of Henoch-Schönlein Purpura (HSP) shows great variability, probably due to selection-bias. Our…
  • Abstract Number: 2595 • 2013 ACR/ARHP Annual Meeting

    Microvascular Abnormalities In Patients With Early Systemic Sclerosis: Less Severe Morphological Changes Compared To Patients With Definite Disease

    Cintia Camargo, Juliana Sekiyama, Maria I. Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil

    Background/Purpose: To analyze the morphological and functional abnormalities of the microcirculation through widefield nailfold capillaroscopy (NFC), videocapillaroscopy and cutaneous microvascular blood flow measurement before and…
  • Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting

    The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients

    Bernadette Lynch1, Henry Penn2, Jennifer Harvey3, Aine Burns4 and Christopher P. Denton5, 1Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, 2Northwick Park Hospital, Harrow, United Kingdom, 3Clinical Immunology, Royal Free Hospital, London, United Kingdom, 4Department of Nephrology, The Royal Free Hospital, London, United Kingdom, 5Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom

    Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…
  • Abstract Number: 2594 • 2013 ACR/ARHP Annual Meeting

    Stabilisation Of Microcirculation In Early Systemic Sclerosis Patients With Diffuse Skin Involvement Following Rituximab Treatment

    Vanessa Smith1, Carmen Pizzorni2, Valeria Riccieri3, Saskia Decuman4, Yves P. Piette1, Ellen Deschepper5, Filip De Keyser1 and Maurizio Cutolo6, 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 3Department of Internal Medicine and Medical Specialities, University Sapienza, Rome, Italy, 4Department of Internal Medicine, Ghent University, Ghent, Belgium, 5Biostatistics Unit, Department of Public Health, Ghent University, Ghent, Belgium, 6University of Genova, Genova, Italy

    Background/Purpose: Microangiopathy in systemic sclerosis is progressive over time [1, 2]. This study assesses microangiopathic evolution by nailfold videocapillarocopic (NVC) analysis after two treatment course…
  • Abstract Number: 2596 • 2013 ACR/ARHP Annual Meeting

    Association Between Nail Fold Capillaroscopy Abnormalities and Thermographic Assessment Of Peripheral Microvascular Dysfunction In An Unselected Cohort Of Patients Under Investigation For Symptoms Of Raynaud’s Phenomenon

    Bhavisha Vasta1, Marina Scolnik1,2, Darren Hart1, Jacqueline A. Shipley1, Sue Brown1, Eleanor Korendowych1, Neil J McHugh1,3 and John D. Pauling1,3, 1Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom

    Background/Purpose: Nail fold capillaroscopy (NC) and infrared thermography (IRT) allow objective assessment of digital microvascular abnormalities in patients with Raynaud’s phenomenon (RP) and have an…
  • « Previous Page
  • 1
  • …
  • 2075
  • 2076
  • 2077
  • 2078
  • 2079
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology